Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines. Upadacitinib Market is thoroughly, accurate and comprehensively assessed in a report focusing on market dynamics, market competition, regional growth, segment analysis, and key growth strategies. Report buyers […]
